Morgan Stanley Vyne Therapeutics Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.12 - $4.91 $36 - $1,473	-300 Reduced 1.27%	23,347 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $4.27 $4,430 - $78,832	-18,462 Reduced 43.84%	23,647 $6,000
Q2 2022 Oct 27, 2022	SELL	$0.37 - $0.71 $1,023 - $1,964	-2,767 Reduced 6.17%	42,109 $16,000
Q2 2022 Aug 15, 2022	SELL	$0.37 - $0.71 $1,023 - $1,964	-2,767 Reduced 6.17%	42,109 $16,000
Q1 2022 Oct 27, 2022	BUY	$0.5 - $1.15 $1,383 - $3,182	2,767 Added 6.57%	44,876 $29,000
Q1 2022 May 13, 2022	SELL	$0.5 - $1.15 $41,394 - $95,206	-82,788 Reduced 64.85%	44,876 $29,000
Q4 2021 Feb 14, 2022	SELL	$0.91 - $1.5 $60,928 - $100,431	-66,954 Reduced 34.4%	127,664 $131,000
Q3 2021 Nov 15, 2021	BUY	$1.39 - $3.47 $270,519 - $675,324	194,618 New	194,618 $271,000

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $176M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.